Researchers have been able to dispense large chunks of abiogenetic code for almost 50 years. But it is only within the past decade that they have been able to do it with admirable attention – adding, deleting and substituting single units of the abiogenetic code just as an editor can dispense a single letter in a document. This newfound adeptness is called gene-editing, the tool is called CRISPR, and it’s being used common to architect plants and livestock and treat ache in people.

For these affidavit the 2020 Nobel Prize in allure has been awarded to Emmanuelle Charpentier, administrator of the Max Planck Unit for the Science of Pathogens in Germany, and Jennifer Doudna, assistant at the University of California, Berkeley, for advertent and transforming CRISPR into a gene-editing technology. It’s the first time two women have shared a Nobel prize.

I’m a CRISPR engineer, absorbed in developing novel CRISPR-based gene-editing tools and commitment methods to advance their attention and function.

In the past, my colleagues and I have created a adaptation of CRISPR that can be controled using light, which allows absolute ascendancy of where and when gene alteration is performed in cells, and can be potentially used in animals and humans. We’ve also created a targeted system that can amalgamation and bear the alteration apparatus to adorable cell types – it’s like GPS for cells. Most recently, we engineered a tool that bigger the speed and attention of CRISPR so it could be used in rapid analytic kits for COVID-19, HIV, HCV and prostate cancer.

While CRISPR scientists like me have been apperception about a Nobel Prize for CRISPR, it was agitative to see Charpentier and Doudna win. This will animate young, accomplished engineers and advisers to enter the field of gene editing, which can be leveraged for designing new diagnostics, treatments and cures for a range of diseases.